MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug
MAIA Biotechnology (NYSE: MAIA) has published preclinical data in Naunyn-Schmiedeberg's Archives of Pharmacology regarding their novel THIO dimer compound. The study, published on February 15, 2025, demonstrates that THIO and its dimer form effectively inhibit Glutathione S-transferase Pi (GSTP1), an enzyme important in cancer progression and chemoresistance.
The research reveals the compound's potential dual mechanism of action for enhancing standard cancer treatments and addressing drug resistance. As part of MAIA's second-generation research platform, which has developed over 80 THIO-like compounds, this breakthrough aims to identify telomere-targeting compounds with improved cancer cell specificity and increased anticancer activity.
The findings suggest that the dimerized form of THIO could enhance chemotherapeutic efficacy through GSTP1 targeting, potentially offering new strategies for combating drug-resistant cancers.
MAIA Biotechnology (NYSE: MAIA) ha pubblicato dati preclinici negli Archivi di Farmacologia di Naunyn-Schmiedeberg riguardanti il loro nuovo composto dimerico THIO. Lo studio, pubblicato il 15 febbraio 2025, dimostra che THIO e la sua forma dimerica inibiscono efficacemente la Glutathione S-transferase Pi (GSTP1), un enzima importante nella progressione del cancro e nella chemioresistenza.
La ricerca rivela il potenziale duplice meccanismo d'azione del composto per migliorare i trattamenti standard contro il cancro e affrontare la resistenza ai farmaci. Come parte della piattaforma di ricerca di seconda generazione di MAIA, che ha sviluppato oltre 80 composti simili al THIO, questa scoperta mira a identificare composti che prendono di mira i telomeri con una maggiore specificità per le cellule tumorali e un'attività anticancro potenziata.
I risultati suggeriscono che la forma dimerizzata di THIO potrebbe migliorare l'efficacia della chemioterapia attraverso il targeting di GSTP1, offrendo potenzialmente nuove strategie per combattere i tumori resistenti ai farmaci.
MAIA Biotechnology (NYSE: MAIA) ha publicado datos preclínicos en los Archivos de Farmacología de Naunyn-Schmiedeberg sobre su nuevo compuesto dimerizado THIO. El estudio, publicado el 15 de febrero de 2025, demuestra que THIO y su forma dimerizada inhiben eficazmente la Glutathione S-transferase Pi (GSTP1), una enzima importante en la progresión del cáncer y la quimiorresistencia.
La investigación revela el potencial mecanismo dual de acción del compuesto para mejorar los tratamientos estándar contra el cáncer y abordar la resistencia a los fármacos. Como parte de la plataforma de investigación de segunda generación de MAIA, que ha desarrollado más de 80 compuestos similares al THIO, este avance tiene como objetivo identificar compuestos que apunten a los telómeros con una mayor especificidad para las células cancerosas y una actividad anticancerígena incrementada.
Los hallazgos sugieren que la forma dimerizada de THIO podría mejorar la eficacia quimioterapéutica a través del targeting de GSTP1, ofreciendo potencialmente nuevas estrategias para combatir los cánceres resistentes a los fármacos.
MAIA Biotechnology (NYSE: MAIA)는 Naunyn-Schmiedeberg의 약리학 아카이브에 그들의 새로운 THIO 이합체 화합물에 대한 전임상 데이터를 발표했습니다. 2025년 2월 15일에 발표된 이 연구는 THIO와 그 이합체 형태가 암 진행과 화학 저항성에 중요한 효소인 글루타티온 S-전이효소 Pi (GSTP1)를 효과적으로 억제함을 보여줍니다.
이 연구는 표준 암 치료를 향상시키고 약물 저항성 문제를 해결하기 위한 화합물의 잠재적인 이중 작용 메커니즘을 밝혀냅니다. MAIA의 2세대 연구 플랫폼의 일환으로 80개 이상의 THIO 유사 화합물을 개발한 이 혁신은 향상된 암세포 특이성과 증가된 항암 활성을 가진 텔로미어 표적 화합물을 식별하는 것을 목표로 하고 있습니다.
결과는 THIO의 이합체 형태가 GSTP1을 표적으로 하여 화학요법의 효능을 향상시킬 수 있음을 시사하며, 약물 저항성 암에 대한 새로운 전략을 제공할 잠재력을 가지고 있습니다.
MAIA Biotechnology (NYSE: MAIA) a publié des données précliniques dans les Archives de Pharmacologie de Naunyn-Schmiedeberg concernant leur nouveau composé dimérique THIO. L'étude, publiée le 15 février 2025, démontre que THIO et sa forme dimérique inhibent efficacement la Glutathione S-transferase Pi (GSTP1), une enzyme importante dans la progression du cancer et la chimiorésistance.
La recherche révèle le potentiel double mécanisme d'action du composé pour améliorer les traitements standards du cancer et aborder la résistance aux médicaments. Dans le cadre de la plateforme de recherche de deuxième génération de MAIA, qui a développé plus de 80 composés similaires au THIO, cette avancée vise à identifier des composés ciblant les télomères avec une spécificité accrue pour les cellules cancéreuses et une activité anticancéreuse augmentée.
Les résultats suggèrent que la forme dimérisée de THIO pourrait améliorer l'efficacité des traitements chimiothérapeutiques grâce au ciblage de la GSTP1, offrant potentiellement de nouvelles stratégies pour lutter contre les cancers résistants aux médicaments.
MAIA Biotechnology (NYSE: MAIA) hat präklinische Daten in den Naunyn-Schmiedeberg's Archives of Pharmacology zu ihrem neuartigen THIO-Dimer veröffentlicht. Die Studie, die am 15. Februar 2025 veröffentlicht wurde, zeigt, dass THIO und seine dimerisierte Form die Glutathione S-transferase Pi (GSTP1) effektiv hemmen, ein wichtiges Enzym für das Fortschreiten von Krebs und Chemoresistenz.
Die Forschung offenbart den potenziellen dualen Wirkmechanismus des Verbindungsstoffs zur Verbesserung der Standardkrebstherapien und zur Bekämpfung der Arzneimittelresistenz. Als Teil von MAIAs Forschungsplattform der zweiten Generation, die über 80 THIO-ähnliche Verbindungen entwickelt hat, zielt dieser Durchbruch darauf ab, telomer-targetierende Verbindungen mit verbesserter Spezifität für Krebszellen und erhöhten antitumoralen Aktivitäten zu identifizieren.
Die Ergebnisse deuten darauf hin, dass die dimerisierte Form von THIO die Wirksamkeit der Chemotherapie durch die gezielte Beeinflussung von GSTP1 erhöhen könnte, was potenziell neue Strategien zur Bekämpfung von arzneimittelresistenten Krebserkrankungen bietet.
- Successful publication of preclinical data in peer-reviewed scientific journal
- Demonstrated potent inhibition of GSTP1, a key enzyme in cancer progression
- Development of 80+ THIO-like compounds showing research pipeline progress
- Potential for enhanced chemotherapeutic efficacy through dual mechanism of action
- Results are only preclinical, requiring further clinical validation
- No concrete efficacy data or success rates provided
- Timeline for potential commercialization not specified
Insights
- Novel THIO dimer shows promise as a new compound with a dual mechanism of action for enhancing standard cancer treatments and overcoming resistance
In a preclinical study, THIO and its new described dimer form were found to be potent inhibitors of Glutathione S-transferase Pi (GSTP1), a key enzyme implicated in cancer progression and chemoresistance and a highly important factor for the detoxification of cancer cells. The findings suggest that the dimerized form of THIO could enhance chemotherapeutic efficacy by effectively targeting GSTP1 and reducing drug resistance. The article, titled “Investigation of the inhibitory effects of the telomere-targeted compounds on glutathione S-transferase P1,” was published on February 15, 2025.
“The esteemed Archives of Pharmacology has published our first peer-reviewed paper about the unique potential of the lead molecule in our second-generation THIO program,” said Vlad Vitoc, M.D., CEO of MAIA. “Preclinical findings illuminate the superior GSTP1 binding affinity and inhibitory potency of this novel prodrug and support continued development of this new strategy for cancer therapy.”
MAIA’s second generation research and discovery platform seeks to identify new telomere-targeting THIO-like compounds with potentially improved specificity towards cancer cells relative to normal cells and with potentially increased anticancer activity. More than 80 THIO-like compounds have been developed as part of the second-generation telomere targeting program.
“Our manuscript highlights the potential of THIO’s dimer as a potent GSTP1 inhibitor and a promising new strategy for enhancing cancer treatment and overcoming drug resistance,” said Chief Scientific Officer Sergei Gryaznov, Ph.D. “Further exploration of the combinatorial effects of THIO with standard chemotherapeutic agents could provide valuable insights for optimizing standard cancer treatment protocols. These efforts could pave the way for novel, targeted strategies in cancer therapy, offering new hope in the fight against drug-resistant cancers.”
About Naunyn–Schmiedeberg’s Archives of Pharmacology
Naunyn–Schmiedeberg’s Archives of Pharmacology, founded in 1873, is the oldest existing pharmacological journal and a dedicated platform for new and significant information on drug action and toxicity of chemical compounds. The peer-reviewed scientific journal covers all fields of experimental and clinical pharmacology as well as toxicology and includes studies in neuropharmacology and cardiovascular pharmacology and those describing drug actions at the cellular, biochemical and molecular levels.
About Ateganosine
Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250320213464/en/
Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com
Source: MAIA Biotechnology, Inc.
FAQ
What are the key findings of MAIA's THIO dimer study published in February 2025?
How many THIO-like compounds has MAIA Biotechnology developed in their second-generation program?
What is the potential impact of MAIA's THIO dimer on cancer treatment?
Where was MAIA's THIO dimer research published and when?
